Desarrollo de un medio de cultivo para potenciar la producción de componentes bioactivos en la microalga autóctona Scenedesmus obliquus

Se estudió el efecto de fuentes de nitrógeno (nitrato de sodio y urea) y de carbono (acetato de sodio y glucosa), así como el estrés salino (cloruro de sodio) sobre cultivo de la microalga Scenedesmus obliquus que potencien la producción de carotenoides totales, proteínas totales y fenoles totales. Se empleó como medio de cultivo base Allen & Arnon y la microalga Scenedesmus obliquus autóctona del Embalse de Salto Grande. Las condiciones experimentales que favorecieron la obtención de biomasa de microalga Scenedesmus obliquus rica en componentes bioactivos fueron: para carotenoides totales 0,24g urea/L; 3,68g glucosa/L y 54,71µmol/(m2s); proteínas totales 0,24g urea/L; 5,02g acetato de sodio/L y 54,71µmol/(m2s) y fenoles totales 31,00g urea/L; 3,68g glucosa/L y 45,04µmol/(m2 s). La concentración de carotenoides totales obtenida fue 473,85±11,00mg β-caroteno/g ms; de proteínas totales 7,09±0,23mg ASB/g ms y de fenoles totales, 16,78±0,84mg EAG/g ms. El estrés salino se desestimó ya que provocó una disminución de la concentración de los componentes de interés. De lo expuesto se concluye que el cultivo de Scenedesmus obliquus, bajo las condiciones de estrés señaladas, representa un proceso biotecnológico atractivo para la obtención de biomasa rica en componentes bioactivos con potencialidad para ser utilizada como aditivo natural en la formulación de alimentos ARK: http://id.caicyt.gov.ar/ark:/s22504559/t9bmfmnb

Problematización acerca de la conformación y la recomendación de consumo del grupo de alimentos opcionales de las Guías Alimentarias para la Población Argentina 2016

Fil: Barreiro, Agustina B. Universidad de Buenos Aires. Facultad de Medicina. Escuela de Nutrición, Argentina.Fil: Cornejo, Carla N. Universidad de Buenos Aires. Facultad de Medicina. Escuela de Nutrición, Argentina.Fil: Siciliano, Sofía. Universidad de Buenos Aires. Facultad de Medicina. Escuela de Nutrición, Argentina.Fil: Taboada, Dora A. Universidad de Buenos Aires. Facultad de Medicina. Escuela de Nutrición, Argentina.Fil: Hagberg, Cecilia. Universidad de Buenos Aires. Facultad de Medicina. Escuela de Nutrición, Argentina.Fil: Flores, Gabriela. Universidad de Buenos Aires. Facultad de Medicina. Escuela de Nutrición, Argentina.Introducción: debido al aumento de las enfermedades crónicas no transmisibles a nivel mundial y su relación con el consumo de productos altos en azúcar, sodio, grasas y energía, se decide realizar una encuesta a Licenciados en Nutrición y Nutricionistas Dietistas para conocer su opinión respecto a la recomendación de consumo de alimentos pertenecientes al grupo denominado “opcionales” establecido por las Guías Alimentarias para la Población Argentina (GAPA) y cuáles de los que actualmente se comercializan, deberían conformar el mismo. Objetivo: problematizar la conformación y la recomendación de consumo del grupo de alimentos opcionales de las GAPA según la opinión de Licenciados en Nutrición y Nutricionistas Dietistas que residen en el país.Introduction: due to the worldwide increase of chronic non-transmissible diseases and its relation with the intake of products high in sugar, sodium, fat and energy consumption, it is decided to make a survey to graduates in Nutrition and 77 Nutritionists Dietitians in order to become acquainted of their opinion about the optional food group intake recommendation established by the Food Guidelines for the Argentine Population (GAPA) and what foods that are currently being marketed, should form part of this group. Goal: to problematize the conformation and intake recommendation of nourishments that are not essential according to the GAPA, based on the opinion of graduates in Nutrition and Nutritionists Dietitians residing in the country

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83–7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97–2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14–1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25–1.30]). Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable

The value of open-source clinical science in pandemic response: lessons from ISARIC

International audienc

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

Background: Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods: This is a multinational, multicentre, prospective cohort study embedded in the ISARIC-WHO COVID-19 Clinical Characterisation Protocol. Patients with laboratory-confirmed SARS-CoV-2 infection who required hospital admission were recruited prospectively. Patients treated with HFNC, NIV, or IMV within the first 24 h of hospital admission were included in this study. Descriptive statistics, random forest, and logistic regression analyses were used to describe clinical characteristics and compare clinical outcomes among patients treated with the different types of advanced respiratory support. Results: A total of 66,565 patients were included in this study. Overall, 82.6% of patients were treated in HIC, and 40.6% were admitted to the hospital during the first pandemic wave. During the first 24 h after hospital admission, patients in HICs were more frequently treated with HFNC (48.0%), followed by NIV (38.6%) and IMV (13.4%). In contrast, patients admitted in lower- and middle-income countries (LMICs) were less frequently treated with HFNC (16.1%) and the majority received IMV (59.1%). The failure rate of non-invasive respiratory support (i.e. HFNC or NIV) was 15.5%, of which 71.2% were from HIC and 28.8% from LMIC. The variables most strongly associated with non-invasive ventilation failure, defined as progression to IMV, were high leukocyte counts at hospital admission (OR [95%CI]; 5.86 [4.83-7.10]), treatment in an LMIC (OR [95%CI]; 2.04 [1.97-2.11]), and tachypnoea at hospital admission (OR [95%CI]; 1.16 [1.14-1.18]). Patients who failed HFNC/NIV had a higher 28-day fatality ratio (OR [95%CI]; 1.27 [1.25-1.30]). Conclusions: In the present international cohort, the most frequently used advanced respiratory support was the HFNC. However, IMV was used more often in LMIC. Higher leucocyte count, tachypnoea, and treatment in LMIC were risk factors for HFNC/NIV failure. HFNC/NIV failure was related to worse clinical outcomes, such as 28-day mortality. Trial registration This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable